VERTEX PHARMACEUTICALS INCORPORATED Funds and ETFs Vertex Pharmaceuticals Incorporated
Equities
VRTX
US92532F1003
Biotechnology & Medical Research
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 426.4 USD | +0.86% |
|
+5.97% | +4.83% |
| 10/05 | Alpine Immune Sciences, Vertex Pharmaceuticals Deal Crosses Another Milestone | MT |
| 07/05 | FOMO is Back |  |
ETFs positioned on Vertex Pharmaceuticals Incorporated
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.02% | 34 M€ | +3.77% | - |
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Calendar
15/05/2024
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
422.8
USD
Average target price
462.1
USD
Spread / Average Target
+9.30%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +4.83% | 11TCr | |
| +10.81% | 11TCr | |
| -0.38% | 2.23TCr | |
| -12.14% | 2.21TCr | |
| -7.66% | 1.87TCr | |
| -36.52% | 1.76TCr | |
| -9.11% | 1.69TCr | |
| +4.61% | 1.38TCr | |
| +34.93% | 1.25TCr | |
| +286.62% | 812.02Cr |
- Stock Market
- Equities
- VRTX Stock
- Funds and ETFs Vertex Pharmaceuticals Incorporated